Esperion Therapeutics Inc. (ESPR) Jumps 5.43% on February 04

Equities Staff |

Esperion Therapeutics Inc. (ESPR) was among the biggest gainers on the Russell 2000 for Thursday February 04 as the stock popped 5.43% to $16.11, representing a gain of $0.83 per share. Some 424,625 shares traded hands on 4,084 trades, compared with an average daily volume of 901,638 shares out of a total float of 22.52 million. The stock opened at $14.92 and traded with an intraday range of $16.45 to $14.44.

After today's gains, Esperion Therapeutics Inc. reached a market cap of $362.78 million. Esperion Therapeutics Inc. has had a trading range between $120.96 and $12.61 over the last year, and it had a 50-day SMA of $21.44 and a 200-day SMA of $54.23.

Esperion Therapeutics Inc is engaged in the research, development and commercialization of therapies for the treatment of patients with elevated levels of elevated levels of LDL-C.

Esperion Therapeutics Inc. is based out of Ann Arbor, MI and has some 21 employees. Its CEO is Timothy M. Mayleben.

For a complete fundamental analysis analysis of Esperion Therapeutics Inc., check out Equities.com’s Stock Valuation Analysis report for ESPR. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.



DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Inovio Pharmaceuticals Inc.

Inovio Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The Company develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and…

Private Markets

Mesa-Marshall 2 Well Project

MESA Resources ("MESA") is sponsoring the development of the two well direct drilling project -- "Mesa-Marshall #1-2". MESA, founded in 1992, is engaged in the acquisition, exploration and development of…

iPRO Network, LLC

We provide the platform, tools, and resources to empower individuals and professionals to market desirable goods and services to the public, taking the place of traditional methods of commerce.